David Amsellem

In a report published Wednesday, Piper Jaffray analyst David Amsellem downgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Overweight to Neutral, but raised the price target from $35.00 to $38.00. In the report, Piper Jaffray noted, “Earlier today, Pacira reported a 2Q13 net loss per share of...

In a report published Wednesday, Piper Jaffray analyst David Amsellem upgraded Questcor Pharmaceuticals (NASDAQ: QCOR) from Neutral to Overweight, and raised the price target from $41.00 to $74.00. In the report, Piper Jaffray noted, “In the wake of a very strong 2Q13 for Questcor (non-GAAP...

In a report published Monday, Piper Jaffray analyst David Amsellem reiterated a Neutral rating on Allergan (NYSE: AGN), but lowered the price target from $90.00 to $79.00. In the report, Piper Jaffray noted, “On Friday, the FDA published draft guidance on bioequivalence (BE) standards for...

In a report published on Wednesday, Piper Jaffray analyst David Amsellem initiated coverage on Cadence Pharmaceuticals (NASDAQ: CADX) with a Neutral rating and a price target of $7.00. In the report, Piper Jaffray noted, "In our survey of nearly three dozen surgeons, the vast majority polled...

In a report published on Wednesday, Piper Jaffray analyst David Amsellem initiated coverage on The Medicines Company (NASDAQ: MDCO) with a rating of Overweight and a price target of $47.00. In the report, Piper Jaffray stated, "We believe MDCO is on the cusp of significant diversification of its...

In a report published on Tuesday, Piper Jaffray analyst David Amsellem raised the price target on Actavis (NYSE: ACT) from $128.00 to $160.00, and reiterated an Overweight rating. In the report, Piper Jaffray noted, "We are reiterating our Overweight rating on Actavis and raising our price...

David Amsellem and Michael Dinerman, analysts at Piper Jaffray, have given an Overweight rating to Salix Pharmaceuticals (NASDAQ: SLXP), a specialty pharmaceutical company dedicated to treatment of a variety of gastrointestinal diseases. The target price is at $58.00, and the stock has been...

Impax Laboratories (NASDAQ: IPXL) has been hit hard in the past week, but Piper Jaffray analysts David Amsellem and Michael Dinerman think that this is mostly due to general market weakness. There are also concerns about stagnant market share for its Adderal XR (AXR) generic. Impax's AXR generic...